Press Releases April 7, 2026 08:00 PM

Barrick Welcomes Ontario Court of Appeal’s Dismissal of Appeal Concerning North Mara Gold Mine

Ontario Court of Appeal Dismisses Human Rights Abuse Appeal Against Barrick's North Mara Gold Mine Operations

By Avery Klein
Share
Twitter Reddit Facebook LinkedIn
B

Barrick Mining Corporation welcomed the Ontario Court of Appeal's dismissal of an appeal regarding human rights abuse allegations linked to its North Mara gold mine in Tanzania. The court upheld a previous ruling that the case should be adjudicated in Tanzania rather than Ontario. Barrick emphasized its zero tolerance policy on human rights violations and highlighted its positive contributions to Tanzanian development.

Barrick Welcomes Ontario Court of Appeal’s Dismissal of Appeal Concerning North Mara Gold Mine
B
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Ontario Court of Appeal dismissed the appeal alleging human rights abuses at North Mara gold mine.
  • Court confirmed that Tanzanian jurisdiction is appropriate for adjudicating such claims.
  • Barrick maintains a strict zero tolerance policy on human rights violations and collaborates closely with Tanzanian government and communities.

TORONTO, April 08, 2026 (GLOBE NEWSWIRE) -- Barrick Mining Corporation (NYSE:B)(TSX:ABX) (“Barrick” or the “Company”) today welcomed the decision by the Ontario Court of Appeal dismissing an appeal by certain Tanzanian residents alleging human rights abuses by members of the Tanzanian Police Force in the vicinity of the Company’s North Mara gold mine. This decision upheld an earlier ruling of the Superior Court of Ontario which found that Ontario is not the appropriate forum to consider these claims and that they must be adjudicated in Tanzania.

Evidence filed during this case established that the Tanzanian Police Force acts independently of Barrick, which maintains a zero tolerance policy for human rights violations by employees, contractors or any third parties acting on its behalf.

Barrick's President and Chief Executive Officer Mark Hill said: “Barrick is proud of our work in Tanzania, which we do in close partnership with all levels of government and our host communities. Our work together creates jobs, drives economic development and improves the lives of many Tanzanians.”

About Barrick Mining Corporation

Barrick is a leading global mining, exploration and development company. With one of the largest portfolios of world-class and long-life gold and copper assets in the industry, Barrick’s operations and projects span 17 countries and five continents. Barrick is also the largest gold producer in the United States. We create real, long-term value for all stakeholders through responsible mining, strong partnerships and a disciplined approach to growth. Barrick shares trade on the New York Stock Exchange under the symbol ‘B’ and on the Toronto Stock Exchange under the symbol ‘ABX’.

Investor Relations Contact

Barrick Mining Corporation
Cleve Rueckert, +1 775 397 5443
[email protected]

Media Contact

Brunswick Group
Carole Cable, +44 (0) 20 7404 5959
[email protected]


Risks

  • Potential ongoing legal and reputational risks related to human rights allegations in Tanzania.
  • Dependence on governmental and local partnerships in Tanzania for operational stability.
  • Geopolitical and regulatory risks inherent in operating in multiple international jurisdictions, including Tanzania.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026